Boltz Partners with Takeda to Expand Use of AI in Drug Discovery
Friday, June 19, 2026
Boltz PBC, an applied artificial intelligence research company, has announced a collaboration with Takeda to deploy its advanced biomolecular AI models and platform across Takeda’s research organisation.
The partnership will provide Takeda’s discovery teams with access to Boltz’s latest proprietary biomolecular foundation models, including BoltzMol-1 and BoltzProt-1. These models are designed to support in-silico molecular design and offer capabilities such as structure prediction, affinity estimation and generative design.
Building on its open-source tools already used within the scientific community, Boltz aims to help researchers improve and accelerate drug discovery processes through AI-driven technologies.
Under the agreement, Takeda scientists will gain access to the Boltz platform, including the Boltz Lab interface and the Boltz API. The API can be integrated into existing research workflows and is designed to work with large language model agents, enabling researchers to manage complex design and prediction tasks using natural language.
The collaboration also includes joint work on selected research programmes, where Boltz scientists will help fine-tune models for specific biological targets. Takeda will retain ownership of any compounds generated through the use of the Boltz platform and models.
Boltz stated that the partnership will make advanced AI tools more accessible to a wide range of researchers, including machine learning specialists, computational scientists, medicinal chemists and protein engineers.
Takeda said the deployment of Boltz’s biomolecular AI models supports its strategy of combining advanced science with artificial intelligence to improve structure prediction, molecular design and the progression of drug discovery programmes.
Source: prnewswire.com
